Canakinumab: all 100 studies that test it

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingNCT07138898Phase 2
• Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal HematopoiesisRecruitingNCT06691217Phase 2
• Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT StudyRecruitingNCT05641831Phase 2
• Canakinumab for the Treatment of Postprandial HypoglycemiaRecruitingNCT05401578Phase 3
• Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung TrialRecruitingNCT04789681Phase 2
• A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaRecruitingNCT04239157Phase 2
• A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)TerminatedNCT04814368Phase 2Results posted
• Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's DiseaseTerminatedNCT04795466Phase 2Results posted
• Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSDCompletedNCT04717635Phase 3Results posted
• A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) PatientsCompletedNCT04581343Phase 1Results posted
• Canakinumab in Covid-19 Cardiac Injury (The Three C Study)CompletedNCT04365153Phase 2Results posted
• Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced PneumoniaCompletedNCT04362813Phase 3Results posted
• This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.TerminatedNCT03968419Phase 2Results posted
• IL-1 Signal Inhibition in Alcoholic HepatitisCompletedNCT03775109Phase 2Results posted
• Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC SubjectsTerminatedNCT03631199Phase 3Results posted
• Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line TherapyTerminatedNCT03626545Phase 3Results posted
• Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-ATerminatedNCT03447769Phase 3Results posted
• Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell AnemiaCompletedNCT02961218Phase 2Results posted
• An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever SyndromesCompletedNCT02911857Phase 3Results posted
• Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary SarcoidosisCompletedNCT02888080Phase 2Results posted
• 1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular InvolvementCompletedNCT02756650Phase 2Results posted
• Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIACompletedNCT02396212Phase 3Results posted
• A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 StudiesCompletedNCT02334748Phase 3Results posted
• ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of CanakinumabCompletedNCT02296424Phase 3Results posted
• Effect of IL--1β Inhibition on Inflammation and Cardiovascular RiskCompletedNCT02272946Phase 2Results posted
• Canakinumab for Treatment of Adult-onset Still's DiseaseTerminatedNCT02204293Phase 2Results posted
• Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic FeversCompletedNCT02059291Phase 3Results posted
• ACZ885 for the Treatment of Abdominal Aortic AneurysmTerminatedNCT02007252Phase 2Results posted
• Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery DiseaseTerminatedNCT01731990Phase 2Results posted
• Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory DiseaseCompletedNCT01576367Phase 3Results posted
• β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)CompletedNCT01470989Phase 3Results posted
• Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis PatientsCompletedNCT01431638Phase 3Results posted
• A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia RheumaticaTerminatedNCT01364389Phase 2Results posted
• Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or IneffectiveTerminatedNCT01362608Phase 3Results posted
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)CompletedNCT01327846Phase 3Results posted
• Canakinumab in Patients With Active Hyper-IgD SyndromeCompletedNCT01303380Phase 2Results posted
• Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory DiseaseCompletedNCT01302860Phase 3Results posted
• The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye PatientsCompletedNCT01250171Phase 2Results posted
• Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).CompletedNCT01242813Phase 2Results posted
• To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the KneeCompletedNCT01160822Phase 2Results posted
• Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.CompletedNCT01080131Phase 3Results posted
• To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes TherapiesCompletedNCT01068860Phase 2Results posted
• Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension StudyCompletedNCT01029652Phase 3Results posted
• Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT PatientsCompletedNCT00995930Phase 2Results posted
• Canakinumab Study in Individuals With Newly Diagnosed Type 1 DiabetesCompletedNCT00947427Phase 2Results posted
• Long Term Study of Canakinumab (ACZ885) in Patients With GoutCompletedNCT00927810Phase 2Results posted
• Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic PatientsTerminatedNCT00900146Phase 2/3Results posted
• An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.CompletedNCT00891046Phase 3Results posted
• Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)CompletedNCT00889863Phase 3Results posted
• Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)TerminatedNCT00886769Phase 3Results posted
• A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)CompletedNCT00819585Phase 2Results posted
• Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout PatientsCompletedNCT00798369Phase 2Results posted
• Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory DiseaseTerminatedNCT00770601Phase 3Results posted
• Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory DiseaseCompletedNCT00685373Phase 3Results posted
• Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute GoutCompletedNCT00663169Phase 2Results posted
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 DiabetesCompletedNCT00605475Phase 2Results posted
• Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT00581945Phase 1/2Results posted
• Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid ArthritisCompletedNCT00554606Phase 2Results posted
• Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid ArthritisCompletedNCT00504595Phase 2Results posted
• Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid ArthritisCompletedNCT00487825Phase 2Results posted
• Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells SyndromeCompletedNCT00465985Phase 3Results posted
• Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid ArthritisCompletedNCT00424346Phase 2Results posted
• Evaluation of Canakinumab in High-Risk Former-SmokersCompletedNCT06038526Phase 2
• A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic CancerActive, not recruitingNCT05984602Phase 1
• A Prevention Trial of Canakinumab in Subjects at High Risk for Lung CancerTerminatedNCT05725343Phase 3
• Using a Contact Dermatitis Model With Biologic Medications to Study Skin InflammationActive, not recruitingNCT05535738Phase 2/3
• Study of Canakinumab in Patients With MyelofibrosisActive, not recruitingNCT05467800Phase 2
• Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS PatientsTerminatedNCT05237713Phase 2
• COVID-19 VaccinE Response in Rheumatology PatientsCompletedNCT05080218Phase 4
• A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung CancerCompletedNCT04905316Phase 2
• Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDSTerminatedNCT04810611Phase 1
• Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESAActive, not recruitingNCT04798339Phase 1/2
• Canakinumab in Patients With COVID-19 and Type 2 DiabetesCompletedNCT04510493Phase 3
• A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell CarcinomaCompletedNCT04028245Early Phase 1
• Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular DystrophyActive, not recruitingNCT03936894Phase 1/2
• Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).TerminatedNCT03742349Phase 1
• Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki DiseaseWithdrawnNCT02980263Phase 2
• A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)CompletedNCT02900664Phase 1
• Ilaris (Canakinumab) in Patient With Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA)Status unknownNCT02775994Phase 1
• Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AFTerminatedNCT01805960Phase 2
• An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)WithdrawnNCT01676948Phase 3
• Efficacy Study of Canakinumab to Treat UrticariaStatus unknownNCT01635127Phase 2
• Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney DiseaseWithdrawnNCT01593527Phase 3
• A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP)TerminatedNCT01589029Phase 1
• Ilaris® Effects in Schnitzler Syndrome (ILESCH)CompletedNCT01390350Phase 2
• ACZ885 in Type 1 Diabetes MellitusWithdrawnNCT01322321Phase 2
• Canakinumab for Pyoderma GangrenosumCompletedNCT01302795Phase 2
• Efficacy and Safety of Canakinumab in Schnitzler SyndromeCompletedNCT01276522Phase 2
• Ilaris (Canakinumab) in the Schnitzler SyndromeCompletedNCT01245127Phase 2
• Ilaris® in Urticarial Vasculitis - Investigation of Treatment ResponsesCompletedNCT01170936Phase 2
• Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)CompletedNCT01148797Phase 2
• The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in CanadaCompletedNCT01105507Phase 3
• Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean FeverCompletedNCT01088880Phase 2
• Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension PhaseCompletedNCT00991146Phase 3
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With MethotrexateCompletedNCT00619905Phase 1/2
• Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid ArthritisTerminatedNCT00505089Phase 1/2
• Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular DegenerationCompletedNCT00503022Phase 1
• Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical SymptomsCompletedNCT00487708Phase 2
• Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)CompletedNCT00426218Phase 1/2
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Healthy Japanese Male VolunteersCompletedNCT00421226Phase 1

← Canakinumab overview